CorpDev.Org
Deal Intelligence Platform & Services for Global M&A / PE
Big Deal
Bain Capital Weighs $4 Billion Stake Sale in Bridge Data Centres Amid Asia’s AI Infrastructure Gold Rush
Bain Capital is exploring a partial exit from Bridge Data Centres (BDC), a Singapore-headquartered hyperscale operator, in a deal that could value the platform at more than $4 billion. The private equity titan is reportedly seeking to divest...
FIFA’s $20 Billion Commercial Pivot: Inside Infantino’s Plan to Institutionalize the World Cup
In a move that signals a fundamental restructuring of global sports governance, FIFA has moved to carve out its commercial operations into a new, for-profit entity valued at $20 billion. The initiative, spearheaded by President Gianni Infantino,...
Grant Thornton to Acquire CBIZ in $5 Billion Landmark Deal Supported by New Mountain Capital
In a transformative move for the professional services industry, Grant Thornton Advisors LLC announced on July 29, 2026, that it has entered into a definitive agreement to acquire CBIZ, Inc. (NYSE: CBZ) in an all-cash transaction valued at...
Blue Owl Weighs $30 Billion Asia Data Center Exit Amid Liquidity Pivot
Blue Owl Capital Inc. is exploring a full or partial divestment of the Asia-Pacific operations of its data center platform, Stack Infrastructure, according to people familiar with the matter. The potential transaction, which could be valued at...
The ‘Big Law’ Breach: Global Insider Trading Takedown Exposes M&A Information Vulnerabilities
TL;DR U.S. prosecutors unsealed a federal indictment on May 6, 2026, charging 30 individuals, including elite corporate attorneys, in a decade-long insider trading scheme that generated tens of millions in illicit profits. The scheme, allegedly led...
Explainers
Private Equity
International
International
Tech, Media & Telecom
Financial Services
Health & Life Sciences
Biogen Shifts M&A Strategy as Apellis Acquisition Pushes Revenue Above Analyst Expectations
CAMBRIDGE, Mass. — Biogen Inc. (NASDAQ: BIIB) has signaled a definitive pivot in its capital allocation strategy following a blockbuster second quarter that saw the company swing from a projected revenue decline to a "growth story." The catalyst...
Bayer Bolsters Ophthalmology Portfolio with $2.45 Billion Acquisition of Perfuse Therapeutics
TL;DR Bayer AG announced on May 6, 2026, its acquisition of Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment and $2.15 billion in milestones. The deal secures Perfuse's lead asset, PER-001, a Phase II...
UCB Acquires Candid Therapeutics for $2.2 Billion in High-Stakes Bet on ‘Immune Reset’
TL;DR Brussels-based biopharma UCB will acquire Candid Therapeutics for up to $2.2 billion, comprised of a $2.0 billion upfront cash payment and $200 million in milestones. The deal centers on Candid's lead asset, Cizutamig, a T-cell engager...
Sun Pharma Nears $12 Billion Acquisition of Organon: A New Frontier for Indian Pharma
TL;DR Mumbai-based Sun Pharmaceutical Industries Ltd. is finalizing a binding $12 billion offer for Organon & Co., marking the largest overseas acquisition in Indian pharma history. The deal is a strategic pivot for Sun Pharma, moving it from a...
Merck’s $6.7 Billion Bid for Terns Pharma: A Strategic Play for Metabolic Leadership
TL;DR Merck & Co. has launched a $6.7 billion all-cash unsolicited offer for Terns Pharma, a biotech firm specializing in small-molecule drug candidates for metabolic disorders like NASH. The acquisition is a strategic move to accelerate...
